每经AI快讯，有投资者在投资者互动平台提问：有报道称，公司拥有微球基质键合技术53项专利，可 将色谱耗材交货周期缩短80%！请问是否属实？公司正在建设色谱耗材生产基地，建成投产后生产的耗 材是否将普遍应用该技术？除了缩短交货周期，该技术还具有哪些特点及优势？ 汉邦科技（688755.SH）8月15日在投资者互动平台表示，公司自主研发的微球基质键合技术已完成初 步研发，产业化基地已启动规划建设，相关产品情况可持续关注公司公告。 （文章来源：每日经济新闻） ...

Core Viewpoint - The article discusses the advantages of domestic substitution in the biopharmaceutical supply chain, emphasizing stability, safety, and cost-effectiveness as key drivers for companies to adopt domestic products over imports [3][4]. Group 1: Domestic Substitution Advantages - The stability and safety of the supply chain are crucial for biopharmaceutical companies, especially during disruptions that could lead to production halts. Domestic sourcing mitigates risks associated with reliance on imported critical materials [3]. - Cost advantages are significant, with domestic chromatography media offering substantial price reductions compared to imported counterparts. This cost-effectiveness is enhanced when considering the overall supply chain, as companies often switch multiple related consumables to domestic options [3]. - Domestic suppliers provide localized technical support, collaborating closely with clients to optimize processes and improve product quality, which fosters a competitive environment focused on comprehensive technical solutions [3]. Group 2: Industry Trends - The trend towards domestic substitution in chromatography media is largely irreversible, with most companies moving from imported to domestic products, and only a few instances of switching between domestic brands [4]. - Large pharmaceutical companies adopt a mixed procurement strategy for chromatography media, balancing between single and multiple suppliers based on their process needs and risk management considerations [5]. - The primary business of the company, Saifen Technology (688758), focuses on the research, development, and production of liquid chromatography materials for drug analysis and purification, positioning itself as a high-tech enterprise with global sales capabilities [5].